API | emicizumab

emicizumab (Hemlibra) Report issue

Biologics mAb Multi-specific Orphan Drug ^FDA Approved ^FDA First in Class

AACT Drugs@FDA MeSH

Active Ingredient History

NOW

Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai. A Phase I clinical trial found that it was well tolerated by healthy subjects. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
emicizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Coagulation factor IX (Homo sapiens) ^UniProt
- Coagulation factor X (Homo sapiens) ^UniProt
Multi-specific: Yes
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$1824.9900 - $13560.2300

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ace910 | emicizumab

Organizations (18)

Research & Development (18)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (2)

Hemophilia A

Hemorrhage

Experimental Indications - Clinical Trial Phases 1-4 (7)

Factor VIII (Phase 4)

Healthy Volunteers (Phase 1)

Hemophilia A ()

Immune Tolerance (Phase 4)

Neoplasms (Phase 4)

von Willebrand Diseases (Phase 1)

von Willebrand Disease, Type 3 (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 27
# of Trial Organizations: 18

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue